A new editorial in the Annals of Internal Medicine criticizes the premarket approval modification process, through which both Medtronic and St. Jude Medical released high-risk products that were later recalled. A new editorial in the Annals of Internal Medicine singled out devices from medtech giants Medtronic (NYSE:MDT) and St. Jude Medical (NYSE:STJ) as examples of how flaws in the FDA’s review process may allow faulty devices onto the market.
Hey, check out all the engineering jobs. Post your resume today!
